Kenny Walter

Dr. Gadani often suggests patients eat smaller meals and do not eat too close to bedtime.

Patients with anti-HBs also had higher APRI scores, FIB-4 scores, and liver stiffness values.

Dr. Akash B. Gadani said overall treatments for managing GERD are effective.

Smoking was not linked to colonic transit times and colonic transit was not associated with IBS symptom severity.

Some of the favorable responses to voxelotor treatment and signs of hematologic response after voxelotor treatment included increased Hb levels, decreased reticulocyte percentage, and decreased total bilirubin.

The HTRA1 and CFH risk alleles, family history of AMD, the LOC387715 risk allele, and cardiovascular disease were all linked to an increased risk of AMD.

Intravenous opioid use for VOC decreased by 52% in inpatient services between 2017-2018, while oral opioid use increased.

C1M, C3M, and C4M were significantly reduced in patients with structuring disease.

Currently many more patients undergo right heart catheterization than is necessary for diagnosing pulmonary hypertension in patients with systemic sclerosis.

There is a growing body of evidence showing the value of rituximab in the treatment of SSc-ILD.

Patients with obesity who had bariatric surgery had lower rates of mortality compared to patients who did not have bariatric surgery.

The agency also granted rare pediatric disease designations for inclacumab and GBT601.

Rituximab-arrx is similar in safety and efficacy to rituximab for patients with moderate to severe rheumatoid arthritis.

In recent years more and more biologics have come on the market for the treatment of IBD.

Prematurity was also linked to infant regurgitation, infant colic, infant dysphasia, and functional constipation.

In data presented at DDW, there was no evidence found showing biologics result in an increased risk of developing malignancies for patients with IBD and PSC.

For pediatric patients, the anti-HBs (+) rates were relatively stable at approximately 60%, but the anti-HBc (+) rates increased significantly with age.

The majority of treatment emergent adverse events were mild to moderate in severity.

The investigators found pharmacotherapy for AUD was associated with a lower incidence of hepatic decompensation in patients with cirrhosis.

AXS-05 also showed superiority to placebo in safety.

New data suggests there is no connection between ustekinumab and the risk of malignancies.

There are several companies preparing new treatments for recurrent C difficile infections.

There are several potential treatments on the horizon for C difficile infections.

Patients treated with ustekinumab are not at an increased risk of malignancies.

Treating the disease could reduce the risk of patient distress.

There are several live microbiota therapeutics in development, including RBX2660.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.

The age of screening for colon cancer has decreased in recent years.

Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.

The treatment recently became the first ever FDA-approved medication for EoE.